Thomas J Cradick, Peng Qiu, Ciaran M Lee, Eli J Fine, Gang Bao 

Slides:



Advertisements
Similar presentations
Lettuce/Sunflower EST CGPDB project. Data analysis, assembly visualization and validation. Alexander Kozik, Brian Chan, Richard Michelmore. Department.
Advertisements

Molecular Therapy - Nucleic Acids
Figure 1. AsCpf1 and LbCpf1-mediated gene editing in human cells
Yuming Lu, Jian-Kang Zhu  Molecular Plant 
Oligonucleotide Delivery to the Lung: Waiting to Inhale
A Method to Evaluate the Quality of Clinical Gene-Panel Sequencing Data for Single- Nucleotide Variant Detection  Chung Lee, Joon S. Bae, Gyu H. Ryu, Nayoung.
Jayne Griffiths, Marco Catoni, Mayumi Iwasaki, Jerzy Paszkowski 
Detection of two Alu insertions in the CFTR gene
by David M. Weinstock, Beth Elliott, and Maria Jasin
CRISPR/Cas9-mediated genome editing of PML in human cell lines.
CRISPR/Cas9 Technology–Based Xenograft Tumors as Candidate Reference Materials for Multiple EML4-ALK Rearrangements Testing  Rongxue Peng, Rui Zhang,
DNA Diagnostics by Surface-Bound Melt-Curve Reactions
Strategy for CRISPR/Cas9-mediated genome editing in ΔEx50 mice
Molecular Therapy - Nucleic Acids
Getting Things Backwards to Prevent Primer Dimers
AGEseq: Analysis of Genome Editing by Sequencing
Mouse Genome Engineering via CRISPR-Cas9 for Study of Immune Function
Rapid Decoding of Sequence-Specific Nuclease-Induced Heterozygous and Biallelic Mutations by Direct Sequencing of PCR Products  Xingliang Ma, Letian Chen,
Volume 7, Issue 1, Pages (April 2014)
Molecular Therapy - Nucleic Acids
Targeting Hepatitis B Virus With CRISPR/Cas9
CRISPR-Cas9 for in vivo Gene Therapy: Promise and Hurdles
USH2A Gene Editing Using the CRISPR System
Molecular Therapy - Nucleic Acids
Jan Hoinka, Phuong Dao, Teresa M Przytycka 
RNA-Guided Genome Editing in Plants Using a CRISPR–Cas System
Fast, Quantitative and Variant Enabled Mapping of Peptides to Genomes
Molecular Therapy - Nucleic Acids
Andrew R. Bassett, Charlotte Tibbit, Chris P. Ponting, Ji-Long Liu 
Volume 154, Issue 6, Pages (September 2013)
Andriana G Kotini, Michel Sadelain, Eirini P Papapetrou 
Molecular Therapy - Nucleic Acids
Human Genomic Deletions Mediated by Recombination between Alu Elements
Volume 18, Issue 4, Pages (April 2010)
Gang Wang, Na Zhao, Ben Berkhout, Atze T Das  Molecular Therapy 
Volume 9, Issue 4, Pages (November 2014)
Targeted Myostatin Gene Editing in Multiple Mammalian Species Directed by a Single Pair of TALE Nucleases  Li Xu, Piming Zhao, Andrew Mariano, Renzhi.
GFP to BFP Conversion: A Versatile Assay for the Quantification of CRISPR/Cas9- mediated Genome Editing  Astrid Glaser, Bradley McColl, Jim Vadolas  Molecular.
Dale Muzzey, Shera Kash, Jillian I. Johnson, Laura M
WRKY20 dual sgRNA approach.
Zhao Zhang, Yuelin Zhang, Fei Gao, Shuo Han, Kathryn S
Volume 25, Issue 1, Pages (January 2017)
Molecular Therapy - Methods & Clinical Development
Olivier Humbert, Nancy Maizels  Molecular Therapy - Nucleic Acids 
521. Multiplex Genome Editing of TCR°/CD52 Genes as a Platform for “Off the Shelf” Adoptive T-Cell Immunotherapies    Molecular Therapy  Volume 22, Pages.
A CRISPR Approach to Gene Targeting
Complete Haplotype Sequence of the Human Immunoglobulin Heavy-Chain Variable, Diversity, and Joining Genes and Characterization of Allelic and Copy-Number.
A Pyrosequencing-Based Assay for the Rapid Detection of the 22q11
Volume 25, Issue 2, Pages (February 2017)
Molecular Therapy - Nucleic Acids
iRNA-PseU: Identifying RNA pseudouridine sites
Molecular Therapy - Nucleic Acids
Volume 23, Issue 3, Pages (March 2015)
Molecular Therapy - Nucleic Acids
Fiona T van den Berg, John J Rossi, Patrick Arbuthnot, Marc S Weinberg 
Zvi Tamari, Naama Barkai  Cell Reports 
Targeted Deletion of an Entire Chromosome Using CRISPR/Cas9
Ciaran M Lee, Thomas J Cradick, Gang Bao  Molecular Therapy 
Molecular Therapy - Nucleic Acids
Jia Liu, Thomas Gaj, Mark C Wallen, Carlos F Barbas 
Multiplexed Mutagenesis Using the Csy4 System in Tomato Protoplasts.
Molecular Therapy - Nucleic Acids
Molecular Therapy - Methods & Clinical Development
Off-target Effects in CRISPR/Cas9-mediated Genome Engineering
Nuclease Target Site Selection for Maximizing On-target Activity and Minimizing Off- target Effects in Genome Editing  Ciaran M Lee, Thomas J Cradick,
Thomas Gaj, Benjamin E Epstein, David V Schaffer  Molecular Therapy 
Molecular Therapy - Nucleic Acids
Development of a Novel Next-Generation Sequencing Assay for Carrier Screening in Old Order Amish and Mennonite Populations of Pennsylvania  Erin L. Crowgey,
Mapping of Small RNAs in the Human ENCODE Regions
Fig. 3 Genome editing of the MSTN gene.
Presentation transcript:

COSMID: A Web-based Tool for Identifying and Validating CRISPR/Cas Off-target Sites  Thomas J Cradick, Peng Qiu, Ciaran M Lee, Eli J Fine, Gang Bao  Molecular Therapy - Nucleic Acids  Volume 3, (January 2014) DOI: 10.1038/mtna.2014.64 Copyright © 2014 American Society of Gene & Cell Therapy Terms and Conditions

Figure 1 COSMID design, search steps and characteristics. (a) COSMID input consists of the guide sequence, type of PAM, allowed number of mismatches, insertions and deletions, genome of interest, and primer design parameters. (b) A flow chart showing the COSMID software design and the major steps in performing the search. (c) The search strings with insertions and deletions in the first six possible positions are shown. Alternate deletions of repeated bases are synonymous. (d) COSMID output in HMTL showing the genomic sites matching the user-supplied criteria in comparison to guide strand R-01 with chromosomal location. Scoring of the mismatches is provided for ranking, as are PCR primers and reference sequence. The right primers, in silico link, amplicon, and digest sizes are provided in the output, but not shown here. Links are provided to each location in the UCSC genome browser, and to the output file as a spreadsheet for further manipulation and primer ordering. (e) Run times were measured for COSMID using variations of guide strands R-01 and R-30, with and without a 5′G, using standard (NGG) or relaxed PAM (NRG). All runs included sites matching the guide strand with three or less mismatches without indels. More matching loci “hits” were identified by allowing single-base insertions or deletions together with ≤2 base mismatches. Allowing primer design increased the run times in proportion to the number of hits. Molecular Therapy - Nucleic Acids 2014 3, DOI: (10.1038/mtna.2014.64) Copyright © 2014 American Society of Gene & Cell Therapy Terms and Conditions

Figure 1 COSMID design, search steps and characteristics. (a) COSMID input consists of the guide sequence, type of PAM, allowed number of mismatches, insertions and deletions, genome of interest, and primer design parameters. (b) A flow chart showing the COSMID software design and the major steps in performing the search. (c) The search strings with insertions and deletions in the first six possible positions are shown. Alternate deletions of repeated bases are synonymous. (d) COSMID output in HMTL showing the genomic sites matching the user-supplied criteria in comparison to guide strand R-01 with chromosomal location. Scoring of the mismatches is provided for ranking, as are PCR primers and reference sequence. The right primers, in silico link, amplicon, and digest sizes are provided in the output, but not shown here. Links are provided to each location in the UCSC genome browser, and to the output file as a spreadsheet for further manipulation and primer ordering. (e) Run times were measured for COSMID using variations of guide strands R-01 and R-30, with and without a 5′G, using standard (NGG) or relaxed PAM (NRG). All runs included sites matching the guide strand with three or less mismatches without indels. More matching loci “hits” were identified by allowing single-base insertions or deletions together with ≤2 base mismatches. Allowing primer design increased the run times in proportion to the number of hits. Molecular Therapy - Nucleic Acids 2014 3, DOI: (10.1038/mtna.2014.64) Copyright © 2014 American Society of Gene & Cell Therapy Terms and Conditions

Figure 2 Comparison of COSMID with other available tools in predicting off-target sites for guide strand R-01. (a) On- and off-target cleavage rates for guide strand R-01. Marked differences are seen in the cleavage rates at off-target sites with identical sequences, but different chromosomal locations, such as OT8 and OT9 (purple), OT6 and OT7 (green stripes), and OT1–OT5 (blue). The R-01 on-target indel rate is shown to the right (red pattern). (b–d) Comparison of COSMID with other available tools in predicting off-target sites for guide strand R-01. (b) Comparison of RO1 off-target sites that contain two mismatches. The cleavage rates at R-01 on-target site and off-target sites OT1–OT10 are listed by decreasing T7EI activity. OT3 and OT9 had activities below T7E1 detection limit. Sites with matching sequences (outside first base) have their names in bold with colors matching that shown in a. Annotated genes corresponding to the sites are listed. Off-target analysis was performed with different online search tools. If the genomic sites with measurable T7E1 activity (shown in a) were identified by a specific tool (such as Cas OFFinder), their rankings in its output (if sortable) are shown. Sites not in the output of that tool are indicated by a dash in a grey box. (c) Comparison of search results for off-target sites that contain deletions or insertions, in which sequence-verified off-target sites with insertions or deletions, which can also be modeled as loci with four mismatches or alternate PAM considered. (d) The sequence-verified off-target sites with insertions or deletions that cannot be modeled as four mismatches or alternate PAM can only be predicted by COSMID. Molecular Therapy - Nucleic Acids 2014 3, DOI: (10.1038/mtna.2014.64) Copyright © 2014 American Society of Gene & Cell Therapy Terms and Conditions